Clinical trial
To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated…
NCT00397956 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00397956 |
|---|---|
| Title | To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053) |
| Official title | An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability & Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sepsis |
| Intervention type | Drug |
| Interventions | MK0826, ertapenem sodium / Duration of Treatment: 14 Days |
| Enrollment | 30 |
| Start date | Sep 1, 2004 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Nov 10, 2006 |
| Last update posted | Oct 30, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: